WO2008075376A8 - Formes polymorphes du bortézomibe et leur procédé de préparation - Google Patents
Formes polymorphes du bortézomibe et leur procédé de préparation Download PDFInfo
- Publication number
- WO2008075376A8 WO2008075376A8 PCT/IN2007/000561 IN2007000561W WO2008075376A8 WO 2008075376 A8 WO2008075376 A8 WO 2008075376A8 IN 2007000561 W IN2007000561 W IN 2007000561W WO 2008075376 A8 WO2008075376 A8 WO 2008075376A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bortezomib
- preparation
- polymorphic forms
- forms
- novel
- Prior art date
Links
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 title abstract 4
- 229960001467 bortezomib Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur deux nouvelles formes polymorphes stables du bortézomibe (formes I et II) et sur leur procédé de préparation. Le bortézomibe (1) est un agent anti-néoplasique utilisé dans le traitement du myélome multiple.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2348CH2006 | 2006-12-18 | ||
IN2348/CHE/2006 | 2006-12-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008075376A1 WO2008075376A1 (fr) | 2008-06-26 |
WO2008075376A8 true WO2008075376A8 (fr) | 2010-04-15 |
Family
ID=39327992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2007/000561 WO2008075376A1 (fr) | 2006-12-18 | 2007-12-03 | Formes polymorphes du bortézomibe et leur procédé de préparation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008075376A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010002836A (es) * | 2007-09-12 | 2010-03-31 | Reddys Lab Ltd Dr | Bortezomib y proceso para la produccion del mismo. |
WO2011099018A1 (fr) * | 2010-02-15 | 2011-08-18 | Hetero Research Foundation | Polymorphes de bortézomib |
WO2011107912A1 (fr) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Formes polymorphes de bortézomib |
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
US9061037B2 (en) | 2010-03-18 | 2015-06-23 | Innopharma, Inc. | Stable bortezomib formulations |
WO2012047845A1 (fr) | 2010-10-05 | 2012-04-12 | App Pharmaceuticals | Formulations de bortézomib stabilisées par de l'acide borique |
US8497374B2 (en) | 2011-05-12 | 2013-07-30 | Scinopharm Taiwan, Ltd. | Process for preparing and purifying bortezomib |
CA2784240C (fr) | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Formulations stables a base de bortezomib |
AU2013346322B2 (en) * | 2012-11-16 | 2016-11-10 | Shilpa Medicare Limited | Crystalline Bortezomib process |
WO2014097306A1 (fr) | 2012-12-21 | 2014-06-26 | Natco Pharma Limited | Forme polymorphe stable et pure du bortézomib |
IN2013MU01431A (fr) * | 2013-04-16 | 2015-06-26 | Cipla Ltd | |
WO2015122702A1 (fr) * | 2014-02-14 | 2015-08-20 | Kyongbo Pharm. Co., Ltd. | Nouvelle forme cristalline de bortézomib et procédé de préparation associé |
WO2016085943A1 (fr) | 2014-11-25 | 2016-06-02 | Rastelli, Luca | Utilisation d'inhibiteurs du système ubiquitine-protéasome pour le traitement de tumeurs associées à la neurofibromatose de type 2 |
EP3031811A1 (fr) | 2014-12-09 | 2016-06-15 | Teva Pharmaceuticals Ltd. | Esters d'acide malique de bortézomib |
CN110312727A (zh) * | 2017-02-17 | 2019-10-08 | 费森尤斯卡比肿瘤学有限公司 | 一种改进的制备硼酸酯的方法 |
JP7263263B2 (ja) * | 2018-02-01 | 2023-04-24 | 日本化薬株式会社 | ボルテゾミブ結晶の製造方法 |
CN110642881A (zh) * | 2019-10-18 | 2020-01-03 | 扬子江药业集团上海海尼药业有限公司 | 一种硼替佐米晶型m及其制备方法和用途 |
US11964993B2 (en) | 2021-07-03 | 2024-04-23 | Shilpa Pharma Lifesciences Limited | Crystalline bortezomib process |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS65253B1 (sr) * | 2004-03-30 | 2024-03-29 | Millennium Pharm Inc | Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline |
WO2006101535A1 (fr) * | 2005-03-23 | 2006-09-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition de la fonction du proteasome pour renforcer l’activite proapoptotique et antitumorale des cytokines |
-
2007
- 2007-12-03 WO PCT/IN2007/000561 patent/WO2008075376A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008075376A1 (fr) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008075376A8 (fr) | Formes polymorphes du bortézomibe et leur procédé de préparation | |
UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
WO2008084223A3 (fr) | Composés chimiques 637 | |
UA83875C2 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
WO2008064351A3 (fr) | (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8 | |
WO2005110994A3 (fr) | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer | |
WO2007050587A3 (fr) | Compositions therapeutiques et procedes | |
WO2008005877A3 (fr) | Inhibiteurs de c-kit et leurs utilisations | |
SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
TW200606162A (en) | Pyrazolopyridine derivatives | |
WO2008033562A3 (fr) | Composés inhibiteurs de kinases | |
IL188475A0 (en) | Pyrido [2,3-d]pyrimidine-2,4-diamine compounds as ptpib inhibitors | |
NO20080129L (no) | Fremgangsmate for fremstilling av dihydrokinazoliner | |
WO2008076392A3 (fr) | Composés utilisables en tant qu'inhibiteurs de protéines kinases | |
TW200738659A (en) | Novel compounds | |
WO2007044950A3 (fr) | Formes cristallines de docetaxel et leurs processus de preparation | |
WO2007109279A3 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
WO2005021536A3 (fr) | Nouveaux composes | |
WO2008054698A3 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
IL185539A0 (en) | Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, preparation method compositions containing same and use | |
WO2009062576A3 (fr) | Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant | |
TW200621703A (en) | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
HK1112228A1 (en) | Substituted azachinzolines having an antiviral action | |
WO2007072092A8 (fr) | Nouveaux derives de phenanthridine utilises comme antagonistes de la bradykinine | |
WO2007100765A3 (fr) | Composants probiotiques modifiés au lysozyme et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07870528 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct app. not ent. europ. phase |
Ref document number: 07870528 Country of ref document: EP Kind code of ref document: A1 |